AdAlta Ltd
1AD
Company Profile
Business description
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation cells and protein based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
Contact
697 Burke Road
Suite 201
CamberwellVIC3124
AUST: +61 394795159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.30 | 4.70 | 0.05% |
| CAC 40 | 8,151.38 | 0.74 | 0.01% |
| DAX 40 | 24,288.40 | 88.90 | 0.37% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,897.42 | 59.65 | 0.61% |
| HKSE | 25,690.53 | 192.40 | 0.75% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 49,507.21 | 505.71 | 1.03% |
| NZX 50 Index | 13,333.40 | 76.63 | 0.58% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,621.40 | 0.10 | -0.00% |
| SSE Composite Index | 3,890.45 | 14.08 | 0.36% |